Institutional & Family Asset Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q3
– Sell
-38
Closed -$2K – 826
2020
Q2
$2K Sell
38
-11
-22% -$528 ﹤0.01% 669
2020
Q1
$2K Buy
49
+12
+32% +$494 ﹤0.01% 619
2019
Q4
$2K Hold
37
– – ﹤0.01% 699
2019
Q3
$1K Sell
37
-1
-3% -$30 ﹤0.01% 759
2019
Q2
$1K Buy
+38
New +$971 ﹤0.01% 775

Other funds holding ACAD

Institutional & Family Asset Management's ACAD Position: Q3 2020 in Review

Institutional & Family Asset Management sold out of Acadia Pharmaceuticals (ACAD) in Q3 2020, closing a stake of 38 shares — an estimated $2K sold.

Institutional & Family Asset Management first reported a position in ACAD in Q2 2019 and held it in 5 quarters. The position peaked at $2K in Q2 2020. 267 funds tracked by Wall St. Rank hold ACAD as of Q3 2020.

  • Institutional & Family Asset Management reported no remaining Acadia Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
  • Institutional & Family Asset Management sold 38 Acadia Pharmaceuticals shares in Q3 2020, an estimated $2K.
  • Institutional & Family Asset Management first reported a position in Acadia Pharmaceuticals in Q2 2019 and held it in 5 quarters.
  • Institutional & Family Asset Management's Acadia Pharmaceuticals position peaked at $2K in Q2 2020.
  • 267 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2020.

Based on Institutional & Family Asset Management's 13F filing for Q3 2020, filed 30 Oct 2020.